Patents Represented by Attorney Jonathan M. Dermott

Find this attorney in the Justia Lawyer Directory

  • Expression of protein GB1 domain fusion proteins in mammalian cells
    Patent number: 8221998
    Abstract: This present invention relates to the use of the B1 domain of Protein G as an epitope tag for over-expression of proteins in mammalian cells.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: July 17, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Kyung Oh Johanson, John J. Trill
  • Method for inhibiting binding to B-cell receptor
    Patent number: 8216576
    Abstract: The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprising: i) a polypeptide having the amino acid sequence of FIG. 1; or ii) a variant of the polypeptide of i).
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: July 10, 2012
    Assignee: Glaxo Group Limited
    Inventors: Stuart Neville Farrow, Allard Kaptein, Jeremy David Alistair Kitson, Alison J. Winder
  • Methods for reducing gluconoylation of proteins
    Patent number: 8173396
    Abstract: The present invention relates to methods of preventing glyconoylation of polypeptides produced in micororganisms.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: May 8, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Alan R. Gardner, Thomas D. Sweitzer, Alexander H. Taylor, Pramathesh S. Patel
  • NOGO-a neutralising immunoglobulin for treatment of neurological diseases
    Patent number: 7988964
    Abstract: The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: August 2, 2011
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Alexandre Eon-Duval, Robert Ian Grundy, Farhana Hussain, Ruth McAdam, Christopher Plumpton, Rabinder Kumar Prinjha, Paul Alexander Wilson
  • Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
    Patent number: 7807793
    Abstract: Chimeric and humanized IL4 MAbs derived from affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: October 5, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Stephen Dudley Holmes, Mitchell Stuart Gross, Daniel R. Sylvester
  • Chimeric and humanised monoclonal antibodies against Interleukin-13
    Patent number: 7807788
    Abstract: The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: October 5, 2010
    Assignee: Glaxo Group Limited
    Inventors: Claire Ashman, Martin John Cassidy, Jonathan Henry Ellis, Trevor Anthony Kenneth Wattam
  • Immunoglobulins which bind NOGO
    Patent number: 7780964
    Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: August 24, 2010
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Paul Andrew Hamblin, Alan Peter Lewis, Paul Alexander Wilson
  • Chromosome-based platforms
    Patent number: 7521240
    Abstract: Artificial chromosomes, including ACes, that have been engineered to contain available sites for site-specific, recombination-directed integration of DNA of interest are provided. These artificial chromosomes permit tractable, efficient, rational engineering of the chromosome for a variety of applications.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: April 21, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Edward Perkins, Carl Perez, Michael Lindenbaum, Amy Greene, Josephine Leung, Elena Fleming, Sandra Stewart
  • Substances and their uses
    Patent number: 7438913
    Abstract: Polypeptides capable of binding human IL-13 and/or of binding human IL-4 in the presence of IL-4 R? can be used in medicine, in diagnosis and in screening for agonists/antagonist of IL-13/IL-4. One such polypeptide is shown in FIG. 1.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: October 21, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Jean-Yves Bonnefoy, Jean-François Gauchat
  • System for providing communication between the interior and the exterior of a compartment
    Patent number: 7431352
    Abstract: A system for making a connection between the interior and exterior of a compartment, comprising a door opening through the compartment wall, a connector body which can engage with the wall, and having a connection port through it, and a removable cover on the connector body. The body is engaged with the door opening, and an inner door within the compartment engages and removes the cover. A preferred construction creates a single line of confidence seal. The system is particularly suited for sterile compartments.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: October 7, 2008
    Assignee: GlaxoSmithKline Biologicals s.a.
    Inventors: Jacques Thilly, Christian Vandecasserie